C
Christopher E. Randolph Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
faculty
10 h-index
36 pubs
1,132 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Christopher E. Randolph's research investigates biological processes across various model organisms and human health conditions. His work includes studies on the impact of human milk oligosaccharides on gene expression and immune response, and the role of Nox4 in bone development in mice. Randolph has also explored the progression of type 2 diabetes in rats, examining ileal transcriptome and morphology changes. His research extends to cancer, with a study integrating multi-omics data to understand triple-negative breast cancer, and to cardiovascular health, mapping methylation quantitative trait loci in congenital heart disease. Further investigations include the effects of phenolic acids on bone loss and adipogenesis in mice, and the characterization of vaginal and gut microbiota in sows for longevity and reproductive performance. He has also examined bacterial and fungal adaptations in piglets fed different milk formulas.
Metrics
- h-index: 10
- Publications: 36
- Citations: 1,132
Selected Publications
-
Obesity and Dietary Soy Protein With Different Isoflavone Levels Alter Fecal Microbial Composition in Zucker Rats Over 9- and 18-Week Periods (2025)
-
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)
-
Phenolic acids prevent sex-steroid deficiency-induced bone loss and bone marrow adipogenesis in mice (2024)
-
Severe Acute Respiratory Syndrome Coronavirus-2 Lambda Variant Collected from a Child from Arkansas and Sequenced (2023)
Collaboration Network
Top Collaborators
Stephanie D. Byrum
Cancer Research Center
15 shared publications
In database
- Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer
- Severe Acute Respiratory Syndrome Coronavirus-2 Lambda Variant Collected from a Child from Arkansas and Sequenced
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 15 shared publications
Aayoung Hong
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Marco Piva
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Sixue Liu
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Willy Hugo
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Shirley H. Lomeli
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Vincent Zoete
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Zhentao Yang
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Jordan J. Lee
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Skylar J. Lo
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Lu Sun
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Agustin Vega-Crespo
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Alejandro J. Garcia
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
David B. Shackelford
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Steven M. Dubinett
Cancer Research Center (US)
13 shared publications
- Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S3 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Data from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S1 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
- Supplementary Table S2 from Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Showing 5 of 13 shared publications
Similar Researchers
Based on overlapping research topics
Rosalia C. M. Simmen
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Jiangchao Zhao
University of Arkansas at Fayetteville
Metabolism and Genetic Disorders
Gut microbiota and health
Immune Response and Inflammation
Renee Fox
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Gut microbiota and health
Immune Response and Inflammation
Christy Simecka
University of Arkansas for Medical Sciences
Gut microbiota and health
Maternal and Perinatal Health Interventions
Cancer-related molecular mechanisms research
Frank A. Simmen
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Maternal and Perinatal Health Interventions
Cancer-related molecular mechanisms research
Olivia Reyes‐Castro
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Bone Metabolism and Diseases
Cancer-related molecular mechanisms research